Asxl1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-gene
| Gene Symbol | ASXL1 |
| Full Name | Additional Sex Combs Like 1, Transcriptional Regulator |
| Chromosomal Location | 20q11.21 |
| NCBI Gene ID | 55324 |
| OMIM | 612990 |
| Ensembl ID | ENSG00000171456 |
| UniProt | Q8IZY3 |
| Associated Diseases | Bohring-Opitz Syndrome, Myelodysplastic Syndrome |
::
ASXL1 (Additional Sex Combs Like 1) is a gene located on chromosome 20q11.21 that encodes a transcriptional regulator protein involved in epigenetic modification and chromatin remodeling. ASXL1 is a member of the ASXL family of proteins which function as cofactors for histone modification enzymes, particularly those involved in histone H3K27 methylation and demethylation. The protein plays important roles in development, cell fate determination, and gene expression regulation through its interactions with Polycomb group proteins and Trithorax group proteins. Mutations in ASXL1 cause Bohring-Opitz syndrome (BAS), a neurodevelopmental disorder characterized by microcephaly, distinctive facial features, and severe developmental delay. Additionally, ASXL1 somatic mutations are commonly found in myelodysplastic syndrome and other myeloid malignancies, though its role in primary neurodegenerative diseases remains an area of active research.
ASXL1 (Additional Sex Combs Like 1) encodes a chromatin-binding protein involved in epigenetic regulation. ASXL1 is a component of the Polycomb repressive complex 2 (PRC2) and regulates histone H3K27 methylation. It also interacts with the histone demethylase LSD1 and plays roles in transcription regulation and development 1.
De novo heterozygous mutations in ASXL1 cause Bohring-Opitz syndrome (also known as Oberklaid-Danks syndrome), a neurodevelopmental disorder characterized by microcephaly, distinctive facial features, feeding difficulties, and developmental delay. Affected individuals may have brain malformations and abnormal movements 2.
ASXL1 has been implicated in the pathogenesis of frontotemporal dementia. Dysregulation of ASXL1 and associated epigenetic changes contribute to microglial activation and neuroinflammation in FTD 3.
While primarily a hematologic malignancy, ASXL1 mutations in myeloid cells may contribute to inflammatory neurodegeneration through cytokine dysregulation.
ASXL1 is expressed in neural stem cells, neurons, and glial cells throughout the brain. High expression is observed in the developing brain and in regions undergoing active neurogenesis.
The study of Asxl1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.